Plant-Based Vaccines Is Estimated To Witness High Growth
Plant-based vaccines make use of plants as bioreactors for the production of vaccine antigens. Compared to traditional methods of vaccine production, plant-based vaccines have advantages such as low-cost production, rapid scale-up, convenient oral delivery, and lack of requirement for industrial fermentation facilities. As infectious diseases continue to pose threats globally and the need for cost-effective vaccination methods rises, plant-based vaccines offer an economically viable alternative to conventional vaccines.
The global Plant-based Vaccines Market is estimated to be valued at US$ 98.19 Mn in 2023 and is expected to exhibit a CAGR of 7.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The opportunity to lower production costs compared to traditional vaccines is expected to drive the growth of the plant-based vaccines market over the forecast period. Plant-based production systems provide cost-saving advantages by eliminating expensive cell culture and downstream processing equipment required for conventional vaccine production methods. With plants, antigens can be produced on a large scale in a relatively short period of time at a low cost. This offers plant-made vaccines viable production technology especially for developing economies where the vaccination rate is low due to infrastructure and budget constraints. Mass production of plant-based vaccines at reduced costs can increase the accessibility of vaccines globally and hence drive the demand.
Porter's Analysis
Threat of new entrants: The threat of new entrants in the plant-based vaccines market is low as this is a niche market requiring substantial R&D investments and clinical trials. However, supportive government regulations are encouraging new players to enter the market.
Bargaining power of buyers: The bargaining power of buyers is moderate as plant-based vaccines are novel technologies and buyers have limited options currently. However, increasing awareness is empowering buyers.
Bargaining power of suppliers: The bargaining power of suppliers is low due to the specialized nature of supplies and intellectual properties involved in plant-based vaccine development. Suppliers face high switching costs.
Threat of new substitutes: The threat of new substitutes is moderate as traditional vaccine technologies and cell-based platforms pose competition. However, plant-based vaccines offer advantages of scalability and cost-effectiveness.
Competitive rivalry: Competition in the market is expected to intensify during the forecast period with the entry of several pipeline candidates.
SWOT Analysis
Strengths: Plant-based production platforms offer scalability, cost-effectiveness, ease of storage & distribution compared to traditional vaccines.
Weaknesses: Regulatory acceptance and intellectual property protection are challenges. Clinical data is limited for some candidate vaccines.
Opportunities: Increasing preference for plant-based therapeutics, supportive government policies for vaccine R&D present lucrative growth opportunities.
Threats: Slow regulatory approvals, failure of pipeline candidates in clinical trials, and competition from conventional and cell-based vaccines restrict market growth.
Key Takeaways
The Global Plant-Based Vaccines Market Growth is expected to witness high during the forecast period due to the increasing focus on developing effective and affordable vaccines against common and emerging infections using plant-based production platforms. The global Plant-based Vaccines Market is estimated to be valued at US$ 98.19 Mn in 2023 and is expected to exhibit a CAGR of 7.0% over the forecast period 2023 to 2030.
Regional analysis: North America dominates the global plant-based vaccines market currently due to supportive government policies and presence of major players in the region. However, Asia Pacific is expected to show highest growth during the forecast period with countries like China and India emerging as lucrative markets.
Key players: Key players operating in the plant-based vaccines market are Medicago, Inc., IBIO, Inc., Icon Genetics GmbH, Lumen Bioscience, Inc., British American Tobacco Plc., Creative Biolabs, Inc., Leaf Expression Systems Ltd., ZYUS Life Sciences Inc., PlantForm Corporation, and Infectious Disease Research Institute (IDRI).
Explore more information on this topic, Please visit-